Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 02, 2024 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal

aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
August 21, 2024 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Participate in September Investor Conferences

aTyr Pharma to Participate in September Investor Conferences
August 13, 2024 16:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update

aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
August 06, 2024 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations

aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations
July 30, 2024 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Research Study with Stanford Medicine

aTyr Pharma announces research study with Stanford Medicine to explore role of anti-NRP2 antibodies in glioblastoma multiforme (GBM), form of brain cancer.
July 22, 2024 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis

aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
June 03, 2024 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”

aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
May 24, 2024 16:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 15, 2024 07:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference

aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
May 14, 2024 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis